Articles: coronavirus.
-
South Korean studies on coronavirus disease-2019 (COVID-19) treatment have described the use of community treatment centers (CTCs), which combine elements of the home and hospital, to isolate and treat mild COVID-19 patients. While the number of South Koreans diagnosed with COVID-19 cases has varied greatly by season, the number of confirmed cases in foreign nationals has shown no seasonality, with an average of around 25 to 30 per day. For foreign patients, accommodation arrangements and travel routes may be difficult; they may also have difficulty accessing medical care, so require careful management. ⋯ Three kinds of foods with medication are served according to the patient's country of origin. In total, 315 patients were admitted to the Ansan CTC between 7 October and 22 November 2020; 145 of them were discharged from the CTC and 26 were transferred to other hospitals. To utilize medical resources efficiently during the pandemic, it is desirable to reserve CTCs exclusively for foreign patients.
-
J. Korean Med. Sci. · Nov 2021
Coronavirus Disease 2019 Cases at Universities and Colleges in Seoul Metropolitan Area.
To facilitate evidence-based policy-making on safe reopening of higher education facilities, there is an urgent need to assess baseline profile of coronavirus disease 2019 (COVID-19) incidents within the university/college settings. We aimed to describe the epidemiology of COVID-19 in universities/colleges in Seoul Metropolitan Area during COVID-19 pandemic period. ⋯ In the setting of rigorous infection prevention measures in combination with on- and off- hybrid classes, COVID-19 incidences and outbreaks were limited in university and college campus area across Seoul Metropolitan Area. The evidence around the infection preventive measures in higher education facilities in Seoul Metropolitan Area, suggest insignificant impact on community transmission.
-
J. Korean Med. Sci. · Nov 2021
Serial Screening for SARS-CoV-2 in Rectal Swabs of Symptomatic COVID-19 Patients.
We used serial rectal swabs to investigate the amount and duration of virus secretion through the gastrointestinal tract and assessed the association between fecal shedding and gastrointestinal symptoms and to clarify the clinical usefulness testing rectal swabs. We enrolled ten adult patients hospitalized with symptomatic coronavirus disease 2019 (COVID-19). Respiratory and stool specimens were collected by physicians. ⋯ The viral loads in the respiratory specimens was higher than those in the rectal specimens, and no rectal specimens were positive after the respiratory specimens became negative. There was no association between gastrointestinal symptoms, pneumonia, severity, and rectal viral load. Rectal swabs may play a role in detecting SARS-CoV-2 in individuals with suspected COVID-19, regardless of gastrointestinal symptoms.
-
Observational Study
SARS-CoV-2 could be spread through hospital medication dispensed to patients: A prospective observational study.
Our objective was to analyze in vitro the persistence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the packaging material of the drugs dispensed to hospital wards. Additionally, to evaluate if the protection with a double plastic bag prevents the contamination of the medication dispensed to an intensive care unit (ICU). On the first part, different materials containing different drugs within an ICU were sampled to confirm the lack of contamination by SARS-CoV-2. ⋯ In the second part, SARS-CoV-2 was found in all surfaces for up to 30 days. The use of double-bag unit-dose system to deliver medication in a pandemic seems effective to prevent the potential transmission of SARS-CoV-2. A striking SARS-CoV-2 RNA stability of up to 30 days was found in the surfaces containing the drugs.
-
Randomized Controlled Trial Multicenter Study
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label phase. Final analyses of efficacy and safety data from the blinded phase of the trial are reported. ⋯ The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).